I

Insilico Medicine

AI for Drug Discovery and Aging Research

Hong Kong (US offices in NYC, Boston)
400+

About Insilico Medicine

Industry: AI Drug Discovery
Founded: 2014
Founders: Alex Zhavoronkov
Status: Private

Funding & Growth

Total Raised: $400M+
Valuation: $1B+
Stage: Series D
Key Investors:
Warburg Pincus Qiming Venture Partners B Capital

✓ Pros

  • • Pioneer in generative AI for drug discovery
  • • Fast-moving clinical programs
  • • Publications and visibility
  • • Global team
  • • Aging research focus

✗ Cons

  • • Distributed team (timezone challenges)
  • • Startup culture intensity
  • • Hong Kong HQ complications
  • • High expectations

Get weekly job alerts